Impact Medical Education | Impact: our unique approach to biosimilars

Our approach is to work with both medical affairs and commercial teams, using our experience and insights to shape programs that:

Simplify communication around the biosimilar story, the regulatory and approval processes, and the concept of extrapolation.

Incorporate peer‑to‑peer collaboration, allowing individuals to act as advocates for the benefits of adopting biosimilars.

Work with early adopters to share how they have successfully introduced biosimilars, in naïve and/or 'switch' patients.

Facilitate effective clinician‑patient conversations that are critical for biosimilar adoption.

Differentiate your biosimilar beyond price.

Our process

To inform the optimal strategy and program, we analyze the challenges and opportunities facing your biosimilar brand in terms of its:

Evidence - We evaluate your biosimilar's totality of evidence and advise on how best to message and communicate this.

Endorsement - We monitor, assess and leverage society guidelines and policy, as well as key opinion leader (KOL) advocacy upon which to build peer-to-peer programs.

Environment - We assess commercialization considerations, such as tendering and contracting, to recommend payor initiatives and value-added services that will ultimately provide sustainability for your biosimilar.

                            Our programs
                        

            Communication programs:
        
            Speaker training
Peer-to-peer programs
Webcasts
Digital content
Launch support material
Standalone meetings
Congress support
Satellite symposia
Patient communications
Payor communications

        

            Strategic planning:
        
            Advisory boards
Brand/message development
KOL mapping
Omnichannel planning
Internal communications
Medical science liaison and sales team training materials
Planning workshops

        

            We have delivered biosimilar programs in the following regions:
        
            UK
EMEA
US
Canada
LATAM
APAC

        

Impact: our unique approach to biosimilars

Our approach is to work with both medical affairs and commercial teams, using our experience and insights to shape programs that:

Simplify communication around the biosimilar story, the regulatory and approval processes, and the concept of extrapolation.

Incorporate peer‑to‑peer collaboration, allowing individuals to act as advocates for the benefits of adopting biosimilars.

Work with early adopters to share how they have successfully introduced biosimilars, in naïve and/or 'switch' patients.

Facilitate effective clinician‑patient conversations that are critical for biosimilar adoption.

Differentiate your biosimilar beyond price.

Our process

To inform the optimal strategy and program, we analyze the challenges and opportunities facing your biosimilar brand in terms of its:

Our programs

Communication programs:

Strategic planning:

We have delivered biosimilar programs in the following regions:

Discover the biosmilar support we offer

Is your product established and defending its position?

Are you launching and/or establishing a biosimilar?

Do you have a portfolio of therapies you're marketing?

Want to know about the biosimilar scene?

Or return to the biosimilars home page

Impact: biosimilar specialists